Neil Kumar, BridgeBio CEO
May 13, 2022 07:33 AM EDT
Deals
Bioregnum

Work­ing to right the ship, Bridge­Bio's Neil Ku­mar adds a $110M deal right on top of his cash haul from Bris­tol My­ers

With­in hours of is­su­ing word that Bridge­Bio $BBIO had pulled in $90 mil­lion from its SHP2 li­cens­ing deal with Bris­tol My­ers Squibb, CEO Neil Ku­mar …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times